In a randomised pilot trial of 79 patients with AML or MDS having 8/8 HLA-matched donor transplants, ATG plus post-transplant cyclophosphamide gave similar 100-day survival to ATG alone (94.9% vs 95.0%, p>0.9); median neutrophil engraftment was slower (22 vs 19 days).
RCTn = 79
Walker et al. A randomized pilot trial comparing anti-thymocyte globulin with anti-thymocyte globulin plus post transplant cyclophosphamide for prophylaxis against acute and chronic graft versus host disease in matched donor hematopoietic cell transplants - a study from the Cell Therapy Transplant Canada/ Australasian Leukemia Lymphoma Group Consortium